Federal officials announced Ozempic, Wegovy and 13 other drugs are on a list of medications the government is targeting for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...

Semtech's share surged 8% after UBS initiated coverage with a Buy rating, citing a key product win in Nvidia's Blackwell platform. Read more here.

UBS initiated coverage of Semtech Corporation (NASDAQ:SMTC) with a "Buy" rating and a price target of $85, given the company’s pivot to artificial intelligence networking as a growth driver.

The White House on Friday said Novo Nordisk's weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to ...

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...

Biden administration selects 15 new medications up for price negotiations including weight loss drugs Ozempic and Wegovy.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.